RIGLRigel Pharmaceuticals, Inc.
Price
+71%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, growth steady, the market with it.
Charts
As reported to the SEC, without any scoring.
Rigel Pharmaceuticals, Inc. (RIGL) reported revenue of $79M in Q2 2026 (quarter ended Jun 30, 2026), down 23% from the same quarter a year earlier. That came with a gross margin of 89% and net income of $17M (22% of revenue). For the full year FY2025, revenue was $294M (+64% year on year) and net income $367M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Rigel Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 1, 2026On July 1, 2026, Rigel Pharmaceuticals, Inc. (the "Company") announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company.Director or officer change · Form 8-K
- Jun 17, 2026As previously disclosed in the Current Report on Form 8-K filed by Rigel Pharmaceuticals, Inc. (the “Company”) on May 12, 2026, the Company entered into a License Agreement (the “License Agreement”) with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. (collectively, the …Acquisition or disposition completed · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.